EA201690183A1 - Замещенные пиразолопиридинамины - Google Patents

Замещенные пиразолопиридинамины

Info

Publication number
EA201690183A1
EA201690183A1 EA201690183A EA201690183A EA201690183A1 EA 201690183 A1 EA201690183 A1 EA 201690183A1 EA 201690183 A EA201690183 A EA 201690183A EA 201690183 A EA201690183 A EA 201690183A EA 201690183 A1 EA201690183 A1 EA 201690183A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
substituted
pyrazolopiridinamines
pharmaceutical compositions
stroystva
Prior art date
Application number
EA201690183A
Other languages
English (en)
Inventor
Ульрих Клар
Ларс Вортманн
Георг Кеттшау
Кейт Грахам
Анья Рихтер
Филип Линау
Флориан Пюлер
Кирстин Петерсен
Франциска Зигель
Детлеф Зюльцле
Original Assignee
Байер Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51162789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201690183(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Байер Фарма Акциенгезельшафт filed Critical Байер Фарма Акциенгезельшафт
Publication of EA201690183A1 publication Critical patent/EA201690183A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Настоящее изобретение относится к соединениям замещенных пиразолопиридинов общей формулы I согласно описанию и определению в настоящем документе, к способам получения указанных соединений, к промежуточным соединениям, применяемым для приготовления указанных соединений, к фармацевтическим композициям и комбинациям, содержащим указанные соединения, а также к применению указанных соединений для производства фармацевтических композиций для лечения или профилактики заболевания, в частности гиперпролиферативного и/или ангиогенного расстройства, в виде отдельного препарата или в комбинации с другими активными ингредиентами.
EA201690183A 2013-07-08 2014-07-04 Замещенные пиразолопиридинамины EA201690183A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13175526 2013-07-08
EP13194902 2013-11-28
EP13195131 2013-11-29
PCT/EP2014/064347 WO2015004024A1 (en) 2013-07-08 2014-07-04 Substituted pyrazolo-pyridinamines

Publications (1)

Publication Number Publication Date
EA201690183A1 true EA201690183A1 (ru) 2016-06-30

Family

ID=51162789

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690183A EA201690183A1 (ru) 2013-07-08 2014-07-04 Замещенные пиразолопиридинамины

Country Status (24)

Country Link
US (1) US20160159789A1 (ru)
EP (1) EP3019505A1 (ru)
JP (1) JP2016527216A (ru)
KR (1) KR20160030239A (ru)
CN (1) CN105531279A (ru)
AP (1) AP2016009025A0 (ru)
AU (1) AU2014289415A1 (ru)
CA (1) CA2917380A1 (ru)
CL (1) CL2016000038A1 (ru)
CR (1) CR20160016A (ru)
CU (1) CU20160003A7 (ru)
DO (1) DOP2016000007A (ru)
EA (1) EA201690183A1 (ru)
HK (1) HK1223362A1 (ru)
IL (1) IL243273A0 (ru)
MX (1) MX2016000163A (ru)
NI (1) NI201600006A (ru)
PE (1) PE20160125A1 (ru)
PH (1) PH12016500054A1 (ru)
SG (1) SG11201510391VA (ru)
TN (1) TN2016000005A1 (ru)
UY (1) UY35651A (ru)
WO (1) WO2015004024A1 (ru)
ZA (1) ZA201600275B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201605867A (zh) * 2013-11-20 2016-02-16 拜耳製藥公司 噻吩并嘧啶
US10702526B2 (en) 2015-04-20 2020-07-07 Effector Therapeutics Inc. Inhibitors of immune checkpoint modulators and related methods
GB201520500D0 (en) 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
EP3504213A4 (en) 2016-08-24 2020-01-15 ArQule, Inc. AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE
WO2018134335A1 (en) * 2017-01-20 2018-07-26 Bayer Pharma Aktiengesellschaft Substituted imidazopyridinpyrimidines
US20220257571A1 (en) 2019-07-10 2022-08-18 Funpació Hospital Universitari Vall D'hebron - Institut De Recerca Inhibitor of map kinase interacting serine/threonine kinase 1 (mnk1) and map kinase interacting serine/threonine kinase 2 (mnk2), cancer therapy and therapeutic combinations
CN110483523B (zh) * 2019-08-27 2022-11-22 药雅科技(上海)有限公司 一种吡唑并嘧啶衍生物表皮生长因子抑制剂及其制备方法与用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1651652B1 (en) * 2003-07-24 2006-12-27 Bayer Pharmaceuticals Corporation Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders
WO2007076161A2 (en) * 2005-12-27 2007-07-05 Myriad Genetics, Inc Compounds with therapeutic activity
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
AR072657A1 (es) * 2008-02-29 2010-09-15 Genentech Inc Compuestos inhibidores de raf y metodos para su uso
CA2772316A1 (en) * 2009-08-28 2011-03-03 Array Biopharma Inc. 1h-pyrazolo [3,4-b] pyridine compounds for inhibiting raf kinase
WO2011104340A1 (en) * 2010-02-26 2011-09-01 Boehringer Ingelheim International Gmbh Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
JP2015501793A (ja) * 2011-11-10 2015-01-19 オーエスアイ・ファーマシューティカルズ，エルエルシー ジヒドロプテリジノン類

Also Published As

Publication number Publication date
JP2016527216A (ja) 2016-09-08
CR20160016A (es) 2016-03-04
EP3019505A1 (en) 2016-05-18
HK1223362A1 (zh) 2017-07-28
US20160159789A1 (en) 2016-06-09
PH12016500054A1 (en) 2016-04-04
NI201600006A (es) 2016-02-12
PE20160125A1 (es) 2016-03-17
WO2015004024A1 (en) 2015-01-15
ZA201600275B (en) 2019-04-24
CA2917380A1 (en) 2015-01-15
DOP2016000007A (es) 2016-02-15
KR20160030239A (ko) 2016-03-16
CL2016000038A1 (es) 2016-07-29
UY35651A (es) 2015-02-27
CN105531279A (zh) 2016-04-27
IL243273A0 (en) 2016-02-29
CU20160003A7 (es) 2017-02-02
AU2014289415A1 (en) 2016-01-21
MX2016000163A (es) 2016-04-15
TN2016000005A1 (en) 2017-07-05
SG11201510391VA (en) 2016-01-28
AP2016009025A0 (en) 2016-02-29

Similar Documents

Publication Publication Date Title
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201690183A1 (ru) Замещенные пиразолопиридинамины
EA201891861A1 (ru) 2-(морфолин-4-ил)-1,7-нафтиридины
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591618A1 (ru) Замещенные имидазопиридазины
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
CY1119433T1 (el) Αμινο-υποκατεστημενες ιμιδαζοπυριδαζινες
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201792421A1 (ru) Амидозамещенные производные циклогексана
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
EA201691881A1 (ru) Новые соединения
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
EA201690044A1 (ru) Модуляторы ядерного транспорта и их применение
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
EA201390339A1 (ru) Замещенные имидазопиридазины
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
EA201301181A1 (ru) Триазолопиридины
EA201600398A1 (ru) Тиенопиримидины в качестве ингибиторов mknk1 и mknk2
EA201691293A1 (ru) Гетероарильные производные бутановой кислоты в качестве ингибиторов lta4h
EA201692003A1 (ru) Макроциклические производные пиримидина
EA201600434A1 (ru) Применение производных бензимидазолпролина
EA201791363A1 (ru) Пиразолопиридинамины в качестве ингибиторов mknk1 и mknk2
EA201590697A1 (ru) Производные кетамина